Kalaris Therapeutics (KLRS) Change in Acquisitions & Divestments (2019 - 2026)

Kalaris Therapeutics' Change in Acquisitions & Divestments history runs 7 years deep, the most recent figure standing at $20.0 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments changed N/A year-over-year to $20.0 million; the TTM figure through Mar 2026 stood at $75.0 million (changed N/A YoY), while the FY2025 annual figure was $15.0 million, down 84.21% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $20.0 million, up from $5.0 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $60.0 million in Q3 2022, with the low at $5.0 million in Q4 2024.
• The 4-year median for Change in Acquisitions & Divestments is $35.0 million (2023), against an average of $32.9 million.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments sank 93.68% in 2022, then surged 791.33% in 2023.
• Kalaris Therapeutics' Change in Acquisitions & Divestments stood at $51.0 million in 2022, then plunged by 31.38% to $35.0 million in 2023, then sank by 85.71% to $5.0 million in 2024, then jumped by 300.0% to $20.0 million in 2026.
• Business Quant data shows KLRS's Change in Acquisitions & Divestments at $20.0 million in Q1 2026, $5.0 million in Q4 2024, and $20.0 million in Q3 2024.